Rheumatology Biologic Service
The rheumatology multidisciplinary biologic team
The rheumatology multidisciplinary team consists of: rheumatology doctors; clinical nurse specialists; administration staff and pharmacists.
What are the biologic and small molecule synthetic drugs?
These Drugs were developed scientifically to target inflammatory pathways and proteins in the body that cause the symptoms of rheumatological diseases such as Rheumatoid Arthritis.
Why do we consider biologic drugs differently to DMARDS?
Biologic drugs have revolutionised the treatment of rheumatic diseases and help millions of people around the world. They tend to work more quickly than conventional DMARDS. However, they are considered to be more potent than conventional DMARDs drugs. This means that they may cause patients some side effects, such as increased risk of infection. For this reason, they need to be used sensibly and may not be suitable for all patients.
National Institute for Clinical Excellence (NICE) has published guidance about when patients would be suitable / eligible for treatment with each biologic drug. The conditions we can use these drugs for are: Rheumatoid arthritis (RA); Psoriatic arthritis (PsA); ankylosing spondylitis (AS) and Juvenile idiopathic arthritis (JIA). In rare occasions we use biologic drugs for conditions such as vasculitis, myositis or lupus under the guidance of NHSE specialist commissioning.